Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
The DOI matches its Crossref record.
Abstract
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY-ESO-1 are being developed. In the present study, the safety and immunogenicity of recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-ESO-1 were analyzed in a series of 36 patients with a range of different tumor types. Each construct was first tested individually at two different dose levels and then in a prime-boost setting with recombinant vaccinia-NY-ESO-1 followed by recombinant fowlpox-NY-ESO-1. The vaccines were well tolerated either individually or together. NY-ESO-1-specific antibody responses and/or specific CD8 and CD4 T cell responses directed against a broad range of NY-ESO-1 epitopes were induced by a course of at least four vaccinations at monthly intervals in a high proportion of patients. CD8 T cell clones derived from five vaccinated patients were shown to lyse NY-ESO-1-expressing melanoma target cells. In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Germain, C., Gnjatic, S., Tamzalit, F., Knockaert, S., Remark, R., Goc, J., Lepelley, A., Becht, E., Katsahian, S., Bizouard, G., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1611oc · Cited by 833
Self-citationGoing viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 393
Fu, Y., Liu, S., Zeng, S., & Shen, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1396-4 · Cited by 390
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Genome-wide analysis of cancer/testis gene expression
Hofmann, O., Caballero, O. L., Stevenson, B. J., Chen, Y.-T., Cohen, T., Chua, R., Maher, C. A., Panji, S., Schaefer, U., Kruger, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810777105 · Cited by 336
Self-citationYuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Self-citationOncogenic cancer/testis antigens: prime candidates for immunotherapy
Gjerstorff, M. F., Andersen, M. H., & Ditzel, H. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4694 · Cited by 320
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Self-citationSabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., Jungbluth, A. A., Ritter, G., Aghajanian, C., Bell-McGuinn, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2189 · Cited by 272
Self-citationOdunsi, K., Qian, F., Matsuzaki, J., Mhawech-Fauceglia, P., Andrews, C., Hoffman, E. W., Pan, L., Ritter, G., Villella, J., Thomas, B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703342104 · Cited by 270
Self-citationTestori, A., Richards, J., Whitman, E., Mann, G. B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9941 · Cited by 257
New dimensions in tumor immunology: what does 3D culture reveal?
Feder-Mengus, C., Ghosh, S., Reschner, A., Martin, I., & Spagnoli, G. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.001 · Cited by 139
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Self-citationPollack, S. M. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1419068 · Cited by 47
Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255799 · Cited by 46
Metadata
- Authors
- Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M., Ritter, E., Ritter, G., Jäger, D., Panicali, D., Hoffman, E., Pan, L., Oettgen, H., Old, L. J., & Knuth, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-09-26
- Volume
- 103
- Issue
- 39
- Pages
- 14453-14458
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2163713464
- Cited by
- 216
- References
- 0
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.